Amgen has unveiled a major boost to its U.S. manufacturing capabilities with a $650 million expansion aimed at scaling drug production and integrating advanced biomanufacturing technologies. The investment will primarily enhance the company’s biologics operations at its facility in Juncos, Puerto Rico, one of Amgen’s key hubs for global supply.
The expansion is projected to create nearly 750 jobs, including positions in construction as well as specialized, highly skilled manufacturing roles.
“This expansion underscores Amgen's commitment to U.S. biomanufacturing and to strengthening the resilience of our global supply chain,” said Robert A. Bradway, chairman and chief executive officer at Amgen. “By growing our capacity to deliver innovative medicines with cutting edge technology in our manufacturing plants, we will not only better serve patients but also create high-quality jobs that reinforce America's leadership in biotechnology.”
Local leaders emphasized the impact on Puerto Rico’s economy and workforce. “Amgen's multimillion-dollar expansion reflects a bond of mutual loyalty: Amgen's sustained investment and Puerto Rico's skilled, resilient workforce reinforcing each other over time,” said Puerto Rico Governor Jenniffer González Colón. “This new expansion not only strengthens U.S. supply chain security through reshoring, it also opens new horizons for our people as we build an innovation ecosystem that positions Puerto Rico as the strongest biopharmaceutical hub in the United States.”
Puerto Rico’s economic development officials echoed the significance of the announcement. “Puerto Rico boasts more than 60 years of expertise and excellence in the biopharmaceutical sector, supported by highly skilled talent and world-class infrastructure,” said Sebastián Negrón Reichard, Puerto Rico Secretary of the Department of Economic Development and Commerce. “This investment by Amgen is a testament to how committed we are to advancing a competitive and innovative ecosystem that allows global companies to grow and prosper in Puerto Rico.”
Building on a History of Investment
Amgen noted that it has invested more than $40 billion in manufacturing and research and development since the 2017 passage of the Tax Cuts and Jobs Act (TCJA). The company credited continued federal tax policy support, including provisions in the One Big Beautiful Bill Act of 2025, as a catalyst for its ability to expand domestic operations.
This new project in Juncos follows other major recent investments, including:
- A $600 million science and innovation center in California
- A $900 million manufacturing expansion in Ohio
- A $1 billion manufacturing development in North Carolina
Industry Leadership and Mission
For over four decades, Amgen has played a central role in the biotechnology industry, developing medicines for conditions such as cancer, osteoporosis, heart disease, inflammatory conditions, and rare diseases. The company continues to advance a large pipeline supported by genetics, biologics expertise, and manufacturing innovation.
Amgen has also been widely recognized within the industry. In 2024, it was named one of the “World's Most Innovative Companies” by Fast Company and one of “America's Best Large Employers” by Forbes. It is included in both the Dow Jones Industrial Average® and the Nasdaq-100 Index®.
Stakeholders may follow further updates through the company’s official platforms on X, LinkedIn, Instagram, YouTube, Threads, and at Amgen.com.
Originally reported by Amgen.
.webp)
